Mucin Balls and Corneal Inflammation Events

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Vistakon
Sponsor:
Information provided by (Responsible Party):
Vistakon
ClinicalTrials.gov Identifier:
NCT01437319
First received: September 16, 2011
Last updated: December 9, 2013
Last verified: December 2013

September 16, 2011
December 9, 2013
September 2011
February 2014   (final data collection date for primary outcome measure)
  • Corneal Inflammatory Events [ Time Frame: Number of events from baseline to 7 days ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
  • Corneal Inflammatory Events [ Time Frame: Number of events 7 Days post randomization to one month ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
  • Corneal Inflammatory Events [ Time Frame: Number of events 1 month post randomization to 4 months ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
  • Corneal Inflammatory Events Post 4 Months Randomization to 8 Months [ Time Frame: Post Randomization at 8 months ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
  • Corneal Inflammatory Events [ Time Frame: Number of events 8 months post randomization to 12 months ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
  • Corneal Inflammatory Events [ Time Frame: Post Randomization at 1 month ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
  • Corneal Inflammatory Events [ Time Frame: Post Randomization at 7 days ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
  • Corneal Inflammatory Events [ Time Frame: Post Randomization at 4 months ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
  • Corneal Inflammatory Events [ Time Frame: Post Randomization at 8 months ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
  • Corneal Inflammatory Events [ Time Frame: Post Randomization at 12 months ] [ Designated as safety issue: No ]
    The presence and number of Corneal Inflammatory Events at each visit.
Complete list of historical versions of study NCT01437319 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Mucin Balls and Corneal Inflammation Events
Not Provided

The purpose of this study is to determine if the formation of mucin balls is a marker for protection from inflammatory events to the cornea and if mucin balls play a role in protection during extended contact lens wear.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Corneal Inflammation
  • Device: lotrafilcon A
    To be used during run-in phase only.
  • Device: comfilcon A
    To be assigned at randomization at phase 2 only.
  • Device: balafilcon A
    To be assigned at randomization during phase 2 only.
  • Active Comparator: lotrafilcon A, comfilcon A
    All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to comfilcon A at phase 2.
    Interventions:
    • Device: lotrafilcon A
    • Device: comfilcon A
  • Active Comparator: lotrafilcon A, balafilcon A
    All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to balafilcon A at phase 2.
    Interventions:
    • Device: lotrafilcon A
    • Device: balafilcon A
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
287
Not Provided
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • At least 18 years
  • Free of any active anterior segment disorders that would preclude safe contact lens wear. Active anterior segment disorders and evidence of central microbial keratitis (via a large, >1mm central deep stromal scar) are not allowed. However, evidence of past CLPU will be allowed so long as no more then three such scars are detected bilaterally. Evidence of more than 3 CLPU-like scars places excessive risk on the subject for a subsequent CIE.
  • Correctable vision to 20/25 or better in each eye with spectacles. Amblyopia will be excluded.
  • Flat and steep corneal curvatures from keratometry readings must be between 39.00 and 48.50 D, respectively.
  • Own or agree to purchase a pair of spectacles that can be worn when lenses are removed or in cases of ocular discomfort or emergency.
  • Correctable vision to 20/30 or better at distance with dispensed contact lenses.

Exclusion Criteria:

  • Use/wear of rigid gas permeable lenses within the last 30 days or PMMA lenses within the last 3 months.
  • Immunocompromising disease or insulin dependent diabetes or any other systemic disease that in the investigator's opinion will affect ocular health or increase risk during extended wear.
  • Chronic use of systemic corticosteroids (with the exception of corticosteroid inhalers) or any other medication that in the investigator's opinion will affect ocular physiology or study participation.
  • Ocular disease or condition such as aphakia, corneal dystrophies, corneal edema, external ocular infection, iritis, or had any anterior segment surgery.
  • Use of any ocular medications in the last 2 weeks.
  • Less than or equal to grade 2 on any of the slit lamp observations of: upper tarsal papilla, corneal staining, corneal neovascularization, conjunctival injection, and lid erythema or scales.
  • Currently pregnant or lactating.
  • Smoker
  • Swimming routine of more than twice per month.
Both
18 Years and older
No
Contact: Tawnya Wilson, OD 1-904-443-1834 twilson@its.jnj.com
United States
 
NCT01437319
CR-005016
Not Provided
Vistakon
Vistakon
Not Provided
Not Provided
Vistakon
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP